Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
about
NMR structure of human erythropoietin and a comparison with its receptor bound conformationDevelopment and characterization of novel erythropoiesis stimulating protein (NESP)Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials.Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection.A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration.Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature.Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.Management of cancer-related fatigue.Antioxidant and antiapoptotic effects of darbepoetin-α against traumatic brain injury in rats.Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.Probing protease sensitivity of recombinant human erythropoietin reveals α3-α4 inter-helical loop as a stability determinant.Pharmacokinetic and pharmacodynamic profiles of recombinant human erythropoietin-loaded poly(lactic-co-glycolic acid) microspheres in rats.Evaluation of bioactivity and pharmacokinetic characteristics of PEGylated P.pastoris-expressed erythropoietin.Purification and Characterization of Recombinant Darbepoetin Alfa from Leishmania tarentolae.Kinetic folding mechanism of erythropoietin.Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats.Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.Effects of darbepoetin-alpha in spinal cord ischemia-reperfusion injury in the rabbit
P2860
Q27765719-873D4BBC-5841-44BB-BB9A-97203B8D8968Q28362976-D3E0533C-68B2-4A9C-8622-31514E45E1E8Q34337012-B155AA78-1DEE-4369-A7F0-CE714485EF64Q34631656-2764C70E-0469-4F4C-AAA2-59C5053250F3Q34766672-BEB11413-928F-4775-AAA6-C40D88A5556AQ35066817-8B2B73A9-70BF-449A-BFFE-80E1439B11EEQ35126977-E0BF9271-9177-4426-AECA-1ABD2F0C6502Q36156911-9DA1298F-3A4C-4E98-90D0-4418764936DDQ36220699-8CC90567-DA09-4E9D-BAED-DF489CCEA650Q36736708-3B0144F8-D246-476F-8F54-50B9310474C0Q38848944-292B1BF2-8AB5-407B-B7C9-8344DFCF2DAEQ39234377-237F5E19-784A-4CA7-BFFB-8AB1348D6B5BQ39479432-0647A70C-5661-4AFA-B163-CAB0B4FC3D01Q39695661-02E0A13C-67B6-490F-988D-10B9EC9B35B1Q41911953-650E7827-9FBA-4459-B230-CDF316F32572Q45876557-4F10FC43-A7A1-45C5-BD42-7A67B9B90053Q50788864-B611B984-5E90-431C-AF6B-C617CF8371B7Q56967412-E70A50AE-3033-40AB-9075-1EFA2B032DD4
P2860
Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Epoetin alfa. A review of its ...... use in nonrenal applications.
@en
Epoetin alfa. A review of its ...... use in nonrenal applications.
@en-gb
type
label
Epoetin alfa. A review of its ...... use in nonrenal applications.
@en
Epoetin alfa. A review of its ...... use in nonrenal applications.
@en-gb
prefLabel
Epoetin alfa. A review of its ...... use in nonrenal applications.
@en
Epoetin alfa. A review of its ...... use in nonrenal applications.
@en-gb
P1433
P1476
Epoetin alfa. A review of its ...... use in nonrenal applications.
@en
P2093
P304
P356
10.2165/00003495-199549020-00008
P577
1995-02-01T00:00:00Z
P6179
1001783342